A Study to Evaluate Retisert in the Treatment of Patients With the "Wet" Form of Age-Related Macular Degeneration - Tabular View

Tracking Information
First Received Date ^ICMJE	March 20, 2002
Last Updated Date	May 25, 2006
Start Date ^ICMJE	November 2001
Primary Completion Date
Current Primary Outcome Measures ^ICMJE
Original Primary Outcome Measures ^ICMJE
Change History	Complete list of historical versions of study NCT00032396 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE
Original Secondary Outcome Measures ^ICMJE

Descriptive Information
Brief Title ^ICMJE	A Study to Evaluate Retisert in the Treatment of Patients With the "Wet" Form of Age-Related Macular Degeneration
Official Title ^ICMJE
Brief Summary	A study evaluating Retisert in patients with age-related macular degeneration
Detailed Description
Study Phase	Phase II
Study Type ^ICMJE	Interventional
Study Design ^ICMJE	Treatment
Condition ^ICMJE	Macular Degeneration
Intervention ^ICMJE	Drug: Retisert Implant
Study Arms / Comparison Groups
Publications *
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Active, not recruiting
Enrollment ^ICMJE
Completion Date
Primary Completion Date
Eligibility Criteria ^ICMJE
Gender	Both
Ages	55 Years and older
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	United States

Administrative Information
NCT ID ^ICMJE	NCT00032396
Responsible Party
Study ID Numbers ^ICMJE	CDS FL-004
Study Sponsor ^ICMJE	Control Delivery Systems
Collaborators ^ICMJE	Bausch & Lomb, Inc.
Investigators ^ICMJE
Information Provided By	Control Delivery Systems
Verification Date	December 2002
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP